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Oropharyngeal cancers u m m a r y
Background: Incidence and survival trends of head and neck squamous cell carcinoma (HNSCC) are essen-
tial knowledge for guiding policy making and research.
Methods: The total population of the Netherlands was studied covering 1989–2011. Two-and ﬁve-year
survival and age-standardized incidence rates of HNSCC were assessed in relation to site, gender and
age (15 years-of-age categories).
Results: We recorded a statistically signiﬁcant increase of oral, oropharyngeal and hypopharyngeal carci-
noma for males and females of all ages, varying from 0.6% (hypopharynx in males) to 2.7% (oropharynx in
females) per year. The incidence of laryngeal carcinoma signiﬁcantly decreased for males with 2.3% per
year; for females the situation was stable. In young adults (below 45 years of age) the incidence ﬁgures
were different: signiﬁcant decreasing incidence trends were seen for both genders for carcinomas of the
oropharynx, hypopharynx and larynx. Regarding oral carcinoma, no change was observed for the young
patient group, but for subsites trends were divergent. Carcinoma of the ﬂoor or mouth decreased for both
genders, but carcinoma of the tongue rose by a signiﬁcant 2.8% per year for young males. Five-year sur-
vival trends for all ages showed no change for laryngeal carcinoma, a small improvement for oral and
hypopharyngeal carcinoma, and a substantial and signiﬁcant improvement of survival from 36% to 47%
survival over the total period for oropharyngeal carcinoma.
Conclusion: In the Netherlands for the last two decades, the incidence of oral, oropharyngeal and hypo-
pharyngeal squamous cell carcinoma has increased and survival has improved. The incidence of laryngeal
carcinoma has decreased in males, and remained unchanged in females; survival from laryngeal carci-
noma has not changed.
 2014 Elsevier Ltd. All rights reserved.Introduction
Head and neck cancer comprises malignancies arising in the
upper respiratory and digestive tract and is a frequently occurring
malignancy. Cancers of the oral cavity (including lip), pharynx
(including nasopharynx) and larynx added up to a total number
of approximately 690,000 new cases worldwide in the year 2012,
which is 4.9 % of total cancer incidence [1]. Approximately,
375,000 people died from head and neck cancer worldwide in
2012, 4.6% of total cancer mortality [1]. Recent 2012 estimates
for Europe showed 100,000 and 40,000 new cases for cancers of
the oral cavity/pharynx and larynx, respectively [2].
It is impossible to generalize on recent incidence and mortality
trends for head and neck cancer as there is variation by site, genderand geographical region. Looking at oral cavity cancer, a decrease
of the age standardized incidence has been observed for the US
[3] and Canada [4,5]. In Europe, increasing incidence trends have
been reported for Portugal [6], Denmark [7], Italy (for females only)
[8], France (for females only) [9], the South-East of England [10]
and the Netherlands [11].
Oropharyngeal cancer is frequently reported to show an
increasing incidence in Northern America and North-Western
Europe. This has been described for the US [3], Canada [4],
Scandinavia [7,12,13], France (for females only) [9], south-east
England [10] and the Netherlands [11]. It is likely that the increase
of oropharyngeal cancer must at least for a large part be contrib-
uted to the human papilloma virus (HPV) [14]. HPV-positive head
and neck squamous cell carcinoma (HNSCC) must be considered a
separate group of tumors, with a unique genetic proﬁle [15,16] and
a better prognosis [17,18].
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of oral cancer in younger age groups, reported for the US [19,20],
Scandinavia [21], United Kingdom, Switzerland and Slovakia [22].
Recent studies report an improvement of the ﬁve-year survival
rates in the more developed countries. In the US, the comparison of
time periods 1992–1996 and 2002–2006 gave improved ﬁve-years
survival rates, that varied from 1.9% for patients with larynx cancer
to 23.2% for tonsil cancer [23]. In most European countries there
was an improved 5-years survival for patients suffering from
oral/oropharyngeal cancer during the period from 1990 to 2002
[24]. Survival trends of patients with laryngeal cancer are variable
per country, though in most countries a slight improvement is ob-
served [24].
We previously published incidence trends of head and neck
cancer, in particular on HNSCC in the Netherlands covering the
period 1989–2006 [11]. A statistically signiﬁcant rise of HNSCC of
the oral cavity (females) and oropharynx (males and females)
was reported, contrasting with a decline of laryngeal cancer for
males. The incidence of HNSCC in the younger age group did not
show an increasing trend [11].
The present study highlights more recent data on incidence
trends of HNSCC in the Netherlands covering the longer period
1989–2011, taking age and subsite into account. In addition,
survival trends of this period are reported herein.
Materials and methods
Data were obtained from the Netherlands Cancer Registry cov-
ering the period 1989–2011. This dataset approximates the total
Dutch population, that rose from 14.8 million in 1989 to 16.6 mil-
lion in 2011. Only squamous cell carcinomas (SCC) from the head
and neck region were included: oral cavity, oro- and hypopharynx
and larynx. Subsite coding was according to the ICD-O-3 classiﬁca-
tion [25], while subsite grouping was according to Sobin et al. [26].
The oral cavity was divided in buccal mucosa (ICD-O topography
codes C00.3, C00.4, C06), upper alveolus and gingiva (C03.0), lower
alveolus and gingiva (C03.1), hard palate (C05.0), oral tongue (C02)
and ﬂoor of mouth (C04). The oropharynx was divided in anterior
wall (base of tongue [C01] and vallecula [C10.0]), lateral wall
(C10.2, including tonsil C09), posterior wall (C10.3), superior wall
(soft palate, C05.1 and uvula, C05.2) and remaining or unspeciﬁed
parts (C10.4, C10.8, C10.9). The hypopharynx was categorized as
postcricoid area (C13.0), piriform sinus (C12.9), posterior hypopha-
ryngeal wall (C13.2) and remaining or unspeciﬁed parts (C13.8,
C13.9). Finally, the larynx was included with three subsites: supra-
glottis (C32.1, C10.1), glottis (C32.0) and subglottis (C32.2). As a re-
sult of the restriction to SCC, 5.5% (oral cavity 6.6%; oropharynx
5.8%; hypopharynx 4.5%; larynx 2.2%) of all tumors were excluded
because of the following reasons: adenocarcinoma (2.7%), undiffer-
entiated carcinoma (0.9%), neuroendocrine carcinoma (0.3%) and
other and unspeciﬁed cancers (0.7%). Carcinomas of the lip (C00),
nasopharynx (C11), nasal cavity (C30.0) and sinuses (C31.0 and
C31.1) were not included, because of other etiological factors (lip
and nasopharynx) and low numbers (sinuses). Stage classiﬁcation
was according to the TNM classiﬁcation [26].
Incidence data were expressed as ESR, the European age-stan-
dardized rate per 100,000 inhabitants. Besides, incidence was cal-
culated for four age groups: below 45, 45–59, 60–74 and over
75 years of age. Estimated annual percentage change (EAPC) of
the incidence rates was calculated by log-linear regression. The
trend was considered to be signiﬁcant, when the p-value was
below 0.05. Two and ﬁve year relative survival rates (RSR) were
calculated for different calendar time cohorts. We estimated rela-
tive survival as the ratio of the observed survival to the expected
survival in the general population of the same age and gender,
according to Dickman et al. [27].Results
Incidence trends for the four main sites of HNSCC in the period
1989–2011 are shown for both genders in Fig. 1. The EAPC of
the main sites, but also of the subsites, are shown in Table 1
(all ages and individuals below 45 years) and Supplementary
Table 1 (all age-groups). Two- and ﬁve-years RSR are listed in
Table 2.
HNSCC grouped from all sites
The incidence from 1989–2011 showed a statistically signiﬁ-
cant decreasing trend of 0.4% per year for males (Table 1). In
contrast, there was an increase of 1.7% per year (p < 0.05) in
females. Tumor site considerably inﬂuenced the gender distribu-
tion; the male to female ratio was lowest for oral cavity (1.4) and
highest for the larynx (4.4) (Table 1, the period 2007–2011). The
incidence rate of HNSCC in young adults decreased signiﬁcantly
with 1.8% per year for both genders. The ﬁve-year RSR did not
show an overall change for all age groups, despite positive effects
for some tumor sites (detailed below, Table 2). Two-year RSR
appeared to improve, judged from the statistical difference be-
tween the ﬁrst and last time-cohorts. Distribution of disease stages
was quite constant during the total study period (Supplementary
Table 2).
Oral cavity
The incidence of SCC of the oral cavity has signiﬁcantly in-
creased during the past 23 years, with 0.7% and 1.8% per year in
males and females, respectively (Table 1, Fig. 1). A statistically sig-
niﬁcant increase was seen for most subsites, with a stable situation
for ﬂoor of mouth in both genders, buccal mucosa in males and
hard palate in females (Table 1). In young adults (below 45 years)
the oral carcinoma incidence did not change signiﬁcantly over time
(Table 1). There were, however, divergent results according to sub-
site. Tongue carcinoma showed an increasing trend in both gen-
ders, and for males this increase was statistically signiﬁcant. This
is in contrast with tumors of the ﬂoor of mouth, for which a statis-
tically signiﬁcant decrease was observed for both genders. Also the
incidence of carcinoma of the lower alveolus and gingiva has sig-
niﬁcantly decreased in young males.
A moderate improvement of the 5-year RSR (all ages) was re-
corded for oral cavity SCC, from 56% (95% conﬁdence interval [CI]
54–58%) for cases diagnosed in 1989–94 to 62% (95% CI 60–64%)
in 2007–11 (Table 2).
Oropharynx
Of all head and neck sites, SCC of the oropharynx shows the
highest level of increase in incidence. A signiﬁcant 2.1% and 2.7%
increase per year was observed for males and females, respectively
(Table 1). An increase was observed for all subsites of the
oropharynx, with only small differences in EAPC per subsite. In
contrast to the trend for all age groups combined, a signiﬁcantly
decreasing trend was observed for young adults of both genders
(Table 1).
Five-year RSR showed a consistent increase in the study period
and went from 36% (95% CI 33–39%) in 1989–1994 to 48% (95% CI
45–50%) in 2007–2011 (Table 2).
Hypopharynx
The incidence of hypopharyngeal SCC has increased during the
past 23 years (Table 1). EAPC were signiﬁcantly positive for males
Fig. 1. Incidence trends for HNSCC per site are shown for females (left) and males (right) in the Netherlands. Incidence is expressed as ESR, the European age-standardized
rate per 100,000 inhabitants. For seven of the eight trend lines a signiﬁcant EAPC (estimated annual percentage change) was observed regarding (1) oral cavity: +1.8 (females)
and +0.7 (males); (2) oropharynx: +2.7 (females) and 2.1 (males); (3) hypopharynx: 1.6 (females) and +0.6 (males) and (4) larynx: 2.3 (males) and a not signiﬁcant 0.4
(females).
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increase was for SCC in the piriform sinus in females (2.9% per
year). Regarding young adults, a decreasing trend was noted; this
trend was statistically signiﬁcant, though the absolute numbers
are rather low (Table 2).
The ﬁve year RSR of hypopharyngeal SCC slightly (but not
signiﬁcantly) improved from 27% (95% CI 24–31%) in 1989–1994
to 33% (95% CI 29–37%) in 2007–2011 (Table 2).Larynx
The incidence of laryngeal SCC has decreased for males, and re-
mained stable for females (Table 1, Fig. 1). This makes the larynx
the only site of the head and neck area with a signiﬁcantly decreas-
ing incidence trend, though only in males. This trend existed also in
the young patients, with a signiﬁcant decrease in both males and
females.
Table 1
Gender, site and subsite related incidence trends of HNSCC in the Netherlands 1989–2011 of all age categories and young patients.
Site Subsite Gendera All ages <45 years
EAPCb 95% CI Number/yearc EAPCb 95% CI Number/yearc
Oral cavity All subsites m 0.7 0.2 1.2 428 0.5 1.0 2.0 28.8
f 1.8 1.3 2.4 310 0.2 1.6 1.3 15.2
Buccal mucosa m 0.1 1.3 1.0 68 0.4 4.3 3.6 3.2
f 2.8 1.2 4.4 54 0.0 5.6 5.9 0.6
Upper alveolus and gingiva m 3.0 0.1 5.9 13 1.1 3.4 5.8 1
f 5.1 1.3 9.0 15 1.2 2.7 5.1 0.6
Lower alveolus and gingiva m 1.1 0.0 2.3 37 3.5 6.9 0.0 4
f 2.2 1.2 3.2 39 1.2 4.9 2.8 0.4
Hard palate m 4.0 0.3 7.8 8 0.4 2.6 3.5 2
f 0.0 3.0 3.1 7 2.7 6.6 1.4 0.4
Tongue m 1.8 1.0 2.6 169 2.8 0.5 5.2 18.6
f 2.0 1.2 2.8 123 2.2 0.1 4.5 11.6
Floor of mouth m 0.3 0.9 0.3 133 4.5 7.1 1.8 4.8
f 1.0 0.1 2.7 72 7.5 10.2 4.7 1.6
Oropharynx All subsites m 2.1 1.4 2.7 347 2.7 4.8 0.5 12.2
f 2.7 2.0 3.5 170 4.3 7.1 1.3 3.8
Anterior wall m 2.8 1.8 3.8 109 2.2 5.9 1.7 5.8
f 3.3 1.5 5.1 46 2.0 5.0 1.1 1.8
Lateral wall m 1.9 1.3 2.6 156 3.4 6.8 0.2 5.4
f 2.4 1.4 3.4 79 3.2 7.8 1.7 1.6
Posterior wall m 2.9 0.8 5.1 17 NA 0
f 3.9 0.4 7.5 9 NA 0
Superior wall m 2.1 0.2 4.5 34 0.4 5.0 4.4 0.2
f 3.4 0.9 5.9 23 2.3 5.9 1.3 0.2
Remaining and unspec. parts m 1.4 0.4 3.3 31 3.1 6.3 0.2 0.8
f 2.5 1.1 6.3 14 0.4 0.9 1.7 0.2
Hypopharynx All subsites m 0.6 0.0 1.2 155 4.3 7.3 1.1 2.4
f 1.6 0.4 2.9 41 4.4 8.3 0.3 0.6
Postcricoid area m 1.7 0.4 3.9 8 0.1 1.8 1.6 0.6
f 1.1 4.8 2.7 3 NA 0
Piriform sinus m 0.5 0.3 1.3 109 4.6 8.0 1.1 1.4
f 2.9 0.9 5.0 26 1.8 5.3 1.9 0.6
Posterior hypopharyngeal wall m 1.3 3.5 1.0 12 NA 0
f 2.3 6.2 1.7 5 NA 0
Remaining and unspec. parts m 1.6 0.1 3.4 26 1.0 6.0 4.1 0.4
f 2.0 0.7 4.8 8 NA 0
Larynx All subsites m 2.3 2.6 2.1 568 4.2 5.8 2.6 11.6
f 0.4 0.3 1.1 128 2.6 4.9 0.1 5
Supraglottis m 2.2 2.7 1.7 170 3.1 6.7 0.6 3.4
f 0.7 0.1 1.5 74 1.6 5.0 2.0 2.8
Glottis m 2.4 2.7 2.1 393 4.0 5.7 2.3 8.2
f 0.1 1.0 1.2 52 1.2 5.3 3.2 2.2
Subglottis m 2.7 5.1 0.3 30 NA 0
f 1.2 2.4 4.9 2 NA 0
All sites m 0.4 0.6 0.2 1498 1.8 2.7 0.9 55
f 1.7 1.3 2.1 649 1.8 3.0 0.5 19.6
NA: not applicable, too low numbers.
a Gender: f:female; m:male.
b EAPC: estimated percentage annual change, with 95% conﬁdence intervals (CI) . Statistical signiﬁcant trends are shown in bold.
c Number/year: average of the absolute number of incident cases per year for 2007–2011.
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(Table 2).
Discussion
This study addressed the incidence and survival trends of differ-
ent sites and subsites of HNSCC in the Netherlands covering the
period 1989–2011. A striking ﬁnding is the increase of HNSCC ob-
served for three of the four major sites, the oral cavity, oropharynx
and hypopharynx. This trend is statistically signiﬁcant for all sites
and in both females and males, and is with 2.7% per year the high-
est for female patients with carcinoma of the oropharynx. In con-
trast, for laryngeal carcinoma a decrease for males and a stable
situation for females were observed.
The rising incidence trends for oral cancer parallel those seen in
other European countries [6,7,28] in more or less the same period.
The results are in contrast with the situation in the US [3] andCanada [4], where an approximately 2% decrease per year is
observed.
The increasing incidence of oropharyngeal cancer in the Nether-
lands for the past 23 years is similar to other countries in Europe
[7,10,12,29], the US [3,30], Canada [4] and Australia [31]. The
EAPC-values of the present study are lower than those observed
for France (only females) [9], Denmark [7], Norway [13] and the
US [3]. The results are difﬁcult to compare with those from pan-
European [24] or global [1] studies, as these report on oral cavity
and pharynx (including hypopharynx) carcinoma as a single
category.
The incidence of laryngeal carcinoma shows a decreasing trend
for males and a stable situation for females. These results conﬁrm
the trend that is observed for most European countries [24] and the
US [32].
The three known major risk factors of HNSCC are tobacco use,
excessive alcohol intake and infection with HPV. A change of
Table 2
Survival trends related to site HNSCC 1989–2011.
Site Numbers and period 1989–1994 1995–2000 2001–2006 2007–2011
Oral cavity Numbera of cases 2745 3149 3769 3692
2-Year survivalb (95% CI) 69% (67–71) 71% (69–73) 71% (69–72) 72% (71–74)
5-Year survival (95% CI) 56% (54–58) 58% (56–60) 58% (56–60) 62% (60–64)
Oropharynx Number of cases 1507 2163 2609 2595
2-Year survival 52% (50–55) 55% (53–57) 60% (58–62) 64% (62–66)
5-Year survival 36% (33–39) 41% (38–43) 44% (42–46) 48% (45–50)
Hypopharynx Number of cases 728 963 1047 988
2-Year survival (95% CI) 43% (39–46) 43% (40–47) 44% (41–47) 51% (48–54)
5-Year survival (95% CI) 27% (24–31) 28% (25–31) 30% (27–33) 33% (29–37)
Larynx Number of cases 4114 4174 4206 3496
2-Year survival (95% CI) 82% (80–83) 83% (81–84) 81% (80–82) 83% (81–84)
5-Year survival (95% CI) 71% (69–72) 71% (70–73) 70% (69–72) 70% (68–72)
All sites Number of cases 9094 10,449 11,631 10,771
2-Year survival (95% CI) 70% (69–71) 70% (69–71) 70% (69–71) 72% (72–72)
5-Year survival (95% CI) 57% (56–58) 57% (56–58) 57% (56–58) 58% (57–60)
CI: conﬁdence intervals.
a Number: absolute numbers of patients per site in that period.
b Survival: percentage of surviving patients.
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to the observed changes in incidence. This must be weighed with
the assumption that there generally is more than 20 years between
the ﬁrst genetic event and the eventual clinical detection of HNSCC
[33]. For example, the proportion of male daily smokers has grad-
ually halved during the past 30 years in the Netherlands (http://
www.stivoro.nl, accessed 06-03-2014) and this is probably a rea-
son that larynx cancer incidence decreased in males in the present
report. The unchanged incidence in the last decades observed for
women may be attributed to the increased tobacco consumption
in the 1980s and a smaller decrease in smoking prevalence com-
pared to males in the 1990s [34].
A second risk factor for HNSCC is excessive alcohol consump-
tion. The absolute amount of alcohol consumed per head has
decreased the last 30 years in the Netherlands (http://www.euro.
who.int/hfadb, accessed 06-03-2014), but it is possible that factors
other than the mere quantity per head are more important for the
risk of developing oral and oropharyngeal cancer. It may be that
the absolute number of heavy drinkers and ‘binge drinkers’ has in-
creased in the last three decades.
Presence of an oncogenic HPV infection is another factor that is
associated with an increased risk for mainly oropharyngeal and to
a lesser extent oral carcinoma. Especially for oropharyngeal carci-
noma it has been shown that the percentage and absolute number
of HPV-related carcinomas is increasing in recent years in various
countries [29,30,35]. For the Netherlands the proportion of HPV-
positive oropharyngeal HNSCC increased from 5.1% in 1990 to
29.0% in 2010 [36]. This by itself may contribute to a large part
of the incidence increase of oropharyngeal carcinomas in the Neth-
erlands. For oral carcinomas the contribution of HPV is less prom-
inent. The proportion of HPV-positive SCC of the oral cavity is
estimated to be less than 5% [35], although exact ﬁgures from
the Netherlands are lacking.
Regarding younger patients, the current study provides
evidence that HNSCC incidence decreases at three major sites,
oro- and hypopharynx and larynx, while the oral cavity is stable.
This trend of decrease is in line with results from France that show
a decreasing trend for tonsillar cancer in males [9]. It contrasts,
however, with studies from other countries. The incidence of
oropharyngeal cancer increases in the US [19] and China [37].
Referring to the Dutch situation, in addition to the notion that
the percentage of smokers has decreased over the last 20 years,
there are data showing that the number of teenage smokers hasdecreased from 1990 on (www.stivoro.nl; in Dutch, accessed 06-
03-2013). The question arises whether the decreased level of to-
bacco consumption has translated in less HNSCC in this particular
patient group. The exposure time is short, but this effect of tobacco
may particularly matter for individuals who are highly susceptible
for cancer caused by an inherent sensitivity for DNA damage
[38,39].
The only signiﬁcant increase was observed for tongue carci-
noma in young males, and this conﬁrms results from the US
[19,20,40] and some European countries [21,22]. The reason for
this increase can only be speculated on, and this includes the use
of marihuana, chronic inﬂammation after trauma or oral hygiene
[20]. Remarkably, in France, tongue cancer in young males has de-
creased its incidence the last decades [9].
Five-year relative survival increased by 12% during the study
period for oropharyngeal SCC and 6% for oral and hypopharyngeal
carcinomas, but for this latter group the change was not signiﬁcant.
For all HNSCC combined only a marginal and not signiﬁcant in-
crease (+1%) was observed due to a small decrease for laryngeal
SCC. The increasing survival for patients with oropharyngeal SCC
may for a large extent be explained by the relative proportion
cased by HPV infection. It is well established that the survival of
oropharyngeal SCC is higher when the tumor is HPV related
[17,18,29,41]. This ﬁnding is the reason that currently de-escala-
tion schedules in the group with the most favorable prognosis
are being explored in randomized trials. For oral cancer the sur-
vival rates have improved during recent years in the Netherlands,
but this effect was less substantial than observed for the US [23].
In Europe, survival from oral and oropharyngeal carcinoma in-
creased over the recent 20 years [24,42]. To explain the present re-
sults for oral and oropharyngeal carcinoma it seems that better
response to treatment is a more likely reason than a decrease in
stage of disease at presentation (Supplementary Table 2).
In summary, the incidence of oral, oropharyngeal and hypopha-
ryngeal SCC has increased in the past 23 years; at the same time
survival has improved for patients with SCC at these sites. The inci-
dence of laryngeal carcinoma signiﬁcantly decreased for males,
while the situation was stable for females; survival of patients with
laryngeal carcinoma has not improved.
Conﬂict of interest statement
The authors report no conﬂict of interest.
B.J.M. Braakhuis et al. / Oral Oncology 50 (2014) 670–675 675Appendix A. Supplementary material
Supplementary material associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.oralon-
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